The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Metabolic Disorders Therapeutics Market Research Report 2024

Global Metabolic Disorders Therapeutics Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1713756

No of Pages : 86

Ask Your Query

Metabolic Disorders Therapeutics is a drug used to treat the symptoms of metabolic disorders caused by a variety of causes.

Global Metabolic Disorders Therapeutics market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Metabolic Disorders Therapeutics market research.

Due to the increasing pressure of modern life and the spread of unhealthy lifestyles, the global metabolic disorder treatment market will continue to grow strongly during the forecast period.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Metabolic Disorders Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  •     AbbVie
  •     Novo Nordisk
  •     Actelion Pharmaceuticals
  •     Sanofi
  •     Biocon
  •     Merck
  •     Boehringer Ingelheim
  •     AstraZeneca
  •     CymaBay Therapeutics
  •     Eli Lilly and Company

Segment by Type

  •     Metachromatic Leukodystrophy
  •     Globoid Leukodystrophy
  •     Hepatic Encephalopathy
  •     Others

Segment by Application

  •     Diabetes
  •     Obesity
  •     Hypercholesterolemia
  •     Lysosomal Storage Diseases
  •     Others

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Metabolic Disorders Therapeutics report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Metabolic Disorders Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
        1.2.2 Metachromatic Leukodystrophy
        1.2.3 Globoid Leukodystrophy
        1.2.4 Hepatic Encephalopathy
        1.2.5 Others
    1.3 Market by Application
        1.3.1 Global Metabolic Disorders Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
        1.3.2 Diabetes
        1.3.3 Obesity
        1.3.4 Hypercholesterolemia
        1.3.5 Lysosomal Storage Diseases
        1.3.6 Others
    1.4 Study Objectives
    1.5 Years Considered
    1.6 Years Considered

 2 Global Growth Trends
    2.1 Global Metabolic Disorders Therapeutics Market Perspective (2018-2029)
    2.2 Metabolic Disorders Therapeutics Growth Trends by Region
        2.2.1 Global Metabolic Disorders Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
        2.2.2 Metabolic Disorders Therapeutics Historic Market Size by Region (2018-2023)
        2.2.3 Metabolic Disorders Therapeutics Forecasted Market Size by Region (2024-2029)
    2.3 Metabolic Disorders Therapeutics Market Dynamics
        2.3.1 Metabolic Disorders Therapeutics Industry Trends
        2.3.2 Metabolic Disorders Therapeutics Market Drivers
        2.3.3 Metabolic Disorders Therapeutics Market Challenges
        2.3.4 Metabolic Disorders Therapeutics Market Restraints

 3 Competition Landscape by Key Players
    3.1 Global Top Metabolic Disorders Therapeutics Players by Revenue
        3.1.1 Global Top Metabolic Disorders Therapeutics Players by Revenue (2018-2023)
        3.1.2 Global Metabolic Disorders Therapeutics Revenue Market Share by Players (2018-2023)
    3.2 Global Metabolic Disorders Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Metabolic Disorders Therapeutics Revenue
    3.4 Global Metabolic Disorders Therapeutics Market Concentration Ratio
        3.4.1 Global Metabolic Disorders Therapeutics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disorders Therapeutics Revenue in 2022
    3.5 Metabolic Disorders Therapeutics Key Players Head office and Area Served
    3.6 Key Players Metabolic Disorders Therapeutics Product Solution and Service
    3.7 Date of Enter into Metabolic Disorders Therapeutics Market
    3.8 Mergers & Acquisitions, Expansion Plans

 4 Metabolic Disorders Therapeutics Breakdown Data by Type
    4.1 Global Metabolic Disorders Therapeutics Historic Market Size by Type (2018-2023)
    4.2 Global Metabolic Disorders Therapeutics Forecasted Market Size by Type (2024-2029)

 5 Metabolic Disorders Therapeutics Breakdown Data by Application
    5.1 Global Metabolic Disorders Therapeutics Historic Market Size by Application (2018-2023)
    5.2 Global Metabolic Disorders Therapeutics Forecasted Market Size by Application (2024-2029)

 6 North America
    6.1 North America Metabolic Disorders Therapeutics Market Size (2018-2029)
    6.2 North America Metabolic Disorders Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    6.3 North America Metabolic Disorders Therapeutics Market Size by Country (2018-2023)
    6.4 North America Metabolic Disorders Therapeutics Market Size by Country (2024-2029)
    6.5 United States
    6.6 Canada

 7 Europe
    7.1 Europe Metabolic Disorders Therapeutics Market Size (2018-2029)
    7.2 Europe Metabolic Disorders Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    7.3 Europe Metabolic Disorders Therapeutics Market Size by Country (2018-2023)
    7.4 Europe Metabolic Disorders Therapeutics Market Size by Country (2024-2029)
    7.5 Germany
    7.6 France
    7.7 U.K.
    7.8 Italy
    7.9 Russia
    7.10 Nordic Countries

 8 Asia-Pacific
    8.1 Asia-Pacific Metabolic Disorders Therapeutics Market Size (2018-2029)
    8.2 Asia-Pacific Metabolic Disorders Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
    8.3 Asia-Pacific Metabolic Disorders Therapeutics Market Size by Region (2018-2023)
    8.4 Asia-Pacific Metabolic Disorders Therapeutics Market Size by Region (2024-2029)
    8.5 China
    8.6 Japan
    8.7 South Korea
    8.8 Southeast Asia
    8.9 India
    8.10 Australia

 9 Latin America
    9.1 Latin America Metabolic Disorders Therapeutics Market Size (2018-2029)
    9.2 Latin America Metabolic Disorders Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    9.3 Latin America Metabolic Disorders Therapeutics Market Size by Country (2018-2023)
    9.4 Latin America Metabolic Disorders Therapeutics Market Size by Country (2024-2029)
    9.5 Mexico
    9.6 Brazil

 10 Middle East & Africa
    10.1 Middle East & Africa Metabolic Disorders Therapeutics Market Size (2018-2029)
    10.2 Middle East & Africa Metabolic Disorders Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
    10.3 Middle East & Africa Metabolic Disorders Therapeutics Market Size by Country (2018-2023)
    10.4 Middle East & Africa Metabolic Disorders Therapeutics Market Size by Country (2024-2029)
    10.5 Turkey
    10.6 Saudi Arabia
    10.7 UAE

 11 Key Players Profiles
    11.1 AbbVie
        11.1.1 AbbVie Company Detail
        11.1.2 AbbVie Business Overview
        11.1.3 AbbVie Metabolic Disorders Therapeutics Introduction
        11.1.4 AbbVie Revenue in Metabolic Disorders Therapeutics Business (2018-2023)
        11.1.5 AbbVie Recent Development
    11.2 Novo Nordisk
        11.2.1 Novo Nordisk Company Detail
        11.2.2 Novo Nordisk Business Overview
        11.2.3 Novo Nordisk Metabolic Disorders Therapeutics Introduction
        11.2.4 Novo Nordisk Revenue in Metabolic Disorders Therapeutics Business (2018-2023)
        11.2.5 Novo Nordisk Recent Development
    11.3 Actelion Pharmaceuticals
        11.3.1 Actelion Pharmaceuticals Company Detail
        11.3.2 Actelion Pharmaceuticals Business Overview
        11.3.3 Actelion Pharmaceuticals Metabolic Disorders Therapeutics Introduction
        11.3.4 Actelion Pharmaceuticals Revenue in Metabolic Disorders Therapeutics Business (2018-2023)
        11.3.5 Actelion Pharmaceuticals Recent Development
    11.4 Sanofi
        11.4.1 Sanofi Company Detail
        11.4.2 Sanofi Business Overview
        11.4.3 Sanofi Metabolic Disorders Therapeutics Introduction
        11.4.4 Sanofi Revenue in Metabolic Disorders Therapeutics Business (2018-2023)
        11.4.5 Sanofi Recent Development
    11.5 Biocon
        11.5.1 Biocon Company Detail
        11.5.2 Biocon Business Overview
        11.5.3 Biocon Metabolic Disorders Therapeutics Introduction
        11.5.4 Biocon Revenue in Metabolic Disorders Therapeutics Business (2018-2023)
        11.5.5 Biocon Recent Development
    11.6 Merck
        11.6.1 Merck Company Detail
        11.6.2 Merck Business Overview
        11.6.3 Merck Metabolic Disorders Therapeutics Introduction
        11.6.4 Merck Revenue in Metabolic Disorders Therapeutics Business (2018-2023)
        11.6.5 Merck Recent Development
    11.7 Boehringer Ingelheim
        11.7.1 Boehringer Ingelheim Company Detail
        11.7.2 Boehringer Ingelheim Business Overview
        11.7.3 Boehringer Ingelheim Metabolic Disorders Therapeutics Introduction
        11.7.4 Boehringer Ingelheim Revenue in Metabolic Disorders Therapeutics Business (2018-2023)
        11.7.5 Boehringer Ingelheim Recent Development
    11.8 AstraZeneca
        11.8.1 AstraZeneca Company Detail
        11.8.2 AstraZeneca Business Overview
        11.8.3 AstraZeneca Metabolic Disorders Therapeutics Introduction
        11.8.4 AstraZeneca Revenue in Metabolic Disorders Therapeutics Business (2018-2023)
        11.8.5 AstraZeneca Recent Development
    11.9 CymaBay Therapeutics
        11.9.1 CymaBay Therapeutics Company Detail
        11.9.2 CymaBay Therapeutics Business Overview
        11.9.3 CymaBay Therapeutics Metabolic Disorders Therapeutics Introduction
        11.9.4 CymaBay Therapeutics Revenue in Metabolic Disorders Therapeutics Business (2018-2023)
        11.9.5 CymaBay Therapeutics Recent Development
    11.10 Eli Lilly and Company
        11.10.1 Eli Lilly and Company Company Detail
        11.10.2 Eli Lilly and Company Business Overview
        11.10.3 Eli Lilly and Company Metabolic Disorders Therapeutics Introduction
        11.10.4 Eli Lilly and Company Revenue in Metabolic Disorders Therapeutics Business (2018-2023)
        11.10.5 Eli Lilly and Company Recent Development

 12 Analyst's Viewpoints/Conclusions

 13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock